Prevention or mitigation of T-cell engaging agent-related adverse effects

The present invention relates to the prevention or mitigation of adverse effects related to T cell engaging agents, such as cytokine release syndrome. Specifically, the invention relates to the prevention or mitigation of such side effects using an inhibitor of JAK and/or mTOR.

Saved in:
Bibliographic Details
Main Authors HAEGEL, HELENE CECILE, KLEIN, CHRISTIAN, ZIMMERMANN, TINA, LECLERCQ, GABRIELLE, TOSO, ALBERTO
Format Patent
LanguageChinese
English
Published 01.09.2022
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to the prevention or mitigation of adverse effects related to T cell engaging agents, such as cytokine release syndrome. Specifically, the invention relates to the prevention or mitigation of such side effects using an inhibitor of JAK and/or mTOR.
Bibliography:Application Number: TW202110141678